Trimedyne Lowers Losses; Quarter Revenues Higher

Citing increasing markets for its medical laser devices, Trimedyne Inc. of Santa Ana Monday announced higher revenues and somewhat lowered losses for its first quarter.

For the period ended Dec. 31, the company recorded revenues of $954,000, 27% above those from the year-earlier period. Losses for the quarter were $273,000 versus $428,000 for the previous year period.

Michael R. Henson, president and chief executive, attributed the improved results to the “beginning of the commercialization of our technologies.”

Henson said that although the company expects sales to increase, continued spending for research and development will force the company to operate at a loss for the foreseeable future.

Four-year-old Trimedyne is developing a fiber-optic laser to remove clots and fat deposits in blood vessels as an alternative to heart-bypass surgery. The company began human clinical trials for the laser system late last year.